


Figure S1. Figure S1. Relative survival by age group, stratified by tumour type and, for NSCLC, by treatment group.

(**A**) Relative survival of patients with NSCLC treated with pembrolizumab monotherapy, stratified by age category, (**B**) Relative survival of patients with NSCLC treated with pembrolizumab and chemotherapy, stratified by age category, (**C**) Relative survival of patients with melanoma, stratified by age category.